How do thoracic oncology nurses explain a Lung-RADS 4X result to Spanish-speaking patients who believe it means they have cancer?

The Lung-RADS 4X conversation is one of the most urgent communication failures in thoracic oncology nursing, because the patient who receives a 4X result by mail or patient portal and has no context for what it means will almost always conclude the worst. Lung-RADS 4X is a category within the Lung CT Screening Reporting and Data System, developed by the American College of Radiology, that describes CT findings that are highly suspicious for malignancy based on specific imaging features — spiculated margins, irregular borders, ground-glass opacity with solid components, rapid growth — and that warrant prompt evaluation with PET-CT rather than watchful waiting or short-interval CT. It is not a diagnosis. It describes what the imaging looks like and what the next step is. The critical frame that allows the patient to hear subsequent information accurately is this: Lung-RADS is a language that radiologists use to describe what they see on a CT scan and to recommend what to do next. A Lung-RADS 4X result means the nodule has features that the radiologist considers highly suspicious and that need to be evaluated urgently with a PET-CT scan. It does not say you have cancer. It says the imaging is suspicious enough that we need the next test immediately. The nurse explaining this in Spanish: “Lung-RADS es una escala que los radiólogos usan para describir lo que ven en una tomografía de tórax y para recomendar el próximo paso. Lung-RADS 4X significa que el nódulo tiene características en la imagen que el radiólogo considera altamente sospechosas y que necesitan evaluarse con un PET-CT urgente. No es un diagnóstico de cáncer. No dice que usted tiene cáncer. Dice que la imagen es lo suficientemente sospechosa como para que necesitemos el siguiente estudio de inmediato. El PET-CT va a ayudarnos a determinar si el nódulo es metabólicamente activo — si está consumiendo glucosa de la manera en que los tumores malignos lo hacen — o si es benigno. Muchos nódulos con características sospechosas en la TC resultan ser benignos en el PET. Vamos a obtener esa respuesta. Pero necesitamos el PET primero.” (Lung-RADS is a scale that radiologists use to describe what they see on a chest CT and to recommend the next step. Lung-RADS 4X means the nodule has features in the image that the radiologist considers highly suspicious and that need to be evaluated with an urgent PET-CT. It is not a diagnosis of cancer. It does not say you have cancer. It says the imaging is suspicious enough that we need the next study immediately. The PET-CT will help us determine whether the nodule is metabolically active — whether it is consuming glucose the way malignant tumors do — or whether it is benign. Many nodules with suspicious CT features turn out to be benign on PET. We are going to get that answer. But we need the PET first.)

How do thoracic oncology nurses explain why stage IIIA NSCLC with N2 nodal involvement is not surgically treated?

The stage III surgical candidacy conversation is one of the most emotionally difficult in thoracic oncology nursing because the patient and family experience the surgeon's recommendation as a refusal to help — and sometimes as professional inadequacy — when it is in fact the clinically correct decision. The core misunderstanding is that the patient believes surgery removes cancer, and therefore more surgery, or surgery at a better hospital, would be the way to remove more cancer. The explanation that resolves this has two components. First, why nodal involvement changes the calculation: when lung cancer has spread to the mediastinal lymph nodes on the same side as the tumor (N2 disease), the cancer has demonstrated the ability to travel beyond the lung. Removing the lung lobe with the primary tumor would leave behind microscopic cancer cells in the mediastinum and in the lymphatic pathways that surgery cannot see or reach. A technically successful surgery — one that removed the primary tumor completely — would leave the patient at very high risk for rapid local and distant recurrence because the resected specimen would not contain all the disease. Second, why concurrent chemoradiation treats N2 disease effectively: the chemotherapy and radiation work together — chemotherapy sensitizes the cancer cells to radiation while also treating microscopic systemic disease; the radiation is delivered precisely to the primary tumor and the mediastinal nodes simultaneously, covering both the visible disease and the microscopic lymphatic involvement that surgery cannot address. The nurse explaining this in Spanish: “La razón por la que el cirujano dijo que no opera no es que no puede hacerlo técnicamente. Es que operar no sería el tratamiento correcto para su tipo de cáncer en este momento. Cuando el cáncer se ha extendido a los ganglios del mediastino, quitar el lóbulo del pulmón dejaría células cancerosas microscópicas en el mediastino que la cirugía no puede ver ni alcanzar. El resultado sería una cirugía técnicamente exitosa que no controla el cáncer. La quimioradioterapia combinada trata tanto el tumor primario como los ganglios mediastinales al mismo tiempo. La quimioterapia sensibiliza las células del cáncer a la radiación y trata la enfermedad microscópica en el resto del cuerpo. La radiación se entrega con precisión al tumor y a los ganglios simultáneamente. Después de eso, la inmunoterapia de consolidación puede seguir controlando la enfermedad durante un año.” (The reason the surgeon said he will not operate is not that he cannot do it technically. It is that operating would not be the correct treatment for your type of cancer at this point. When the cancer has spread to the mediastinal lymph nodes, removing the lung lobe would leave microscopic cancer cells in the mediastinum that surgery cannot see or reach. The result would be a technically successful surgery that does not control the cancer. Combined chemoradiation treats both the primary tumor and the mediastinal nodes at the same time. The chemotherapy sensitizes the cancer cells to the radiation and treats the microscopic disease in the rest of the body. The radiation is delivered with precision to the tumor and the nodes simultaneously. After that, consolidation immunotherapy can continue controlling the disease for a year.)

How do thoracic oncology nurses explain why a tunneled pleural catheter cannot be removed when the patient is feeling better?

The tunneled pleural catheter removal conversation is a recurring source of conflict in thoracic oncology nursing because the patient's intuition — I feel better, therefore the problem is resolved, therefore the tube can come out — is entirely rational but clinically incorrect. The catheter treats the symptom (fluid accumulation causing dyspnea) without treating the cause (cancer-related pleural inflammation that continues to produce fluid). The explanation that resolves this has three components. First, why the fluid keeps coming back: in malignant pleural effusion, cancer cells either directly involving the pleura or inflammatory mediators released by the cancer cause the pleural membranes to produce fluid at a rate that overwhelms the normal reabsorption mechanisms. Every time a thoracentesis drains the fluid, the underlying process continues and the fluid returns — in most patients with malignant effusion, within two to four weeks. The catheter addresses this by allowing ongoing drainage at home before the accumulation becomes symptomatic again. Second, what pleurodesis means and when catheter removal is considered: pleurodesis is the adherence of the two pleural layers to each other, eliminating the space where fluid can accumulate. This can occur spontaneously when the catheter is draining regularly — inflammation caused by the catheter itself, combined with drainage keeping the pleural layers in contact, occasionally produces enough scarring to obliterate the pleural space. When drainage volumes consistently fall below 50 mL per session for three consecutive sessions, the team evaluates for spontaneous pleurodesis, and if confirmed, the catheter can be removed. Third, what the removal criteria are in plain terms: the catheter can come out when the pleural space has sealed itself closed, which shows up as consistently very low drainage volumes. The nurse explaining this in Spanish: “El catéter no puede salir todavía porque el problema que lo puso adentro — la producción de líquido por la pleura — no ha parado. Usted se siente mejor porque el catéter está drenando el líquido antes de que se acumule lo suficiente para causarle dificultad para respirar. Pero si quitamos el catéter ahora, el líquido va a volver a acumularse y el problema va a volver. El catéter puede salir cuando los dos capas de la pleura se han sellado entre sí y ya no hay espacio para que el líquido se acumule. Lo que buscamos para saber que eso ocurrió es que el volumen de drenaje caiga consistentemente por debajo de 50 mililitros por sesión durante tres sesiones seguidas. Eso nos indica que la pleura se cerró. Cuando eso ocurra, evaluamos con una imagen si el espacio está sellado y si lo está, el catéter sale.” (The catheter cannot come out yet because the problem that put it in — the production of fluid by the pleura — has not stopped. You are feeling better because the catheter is draining the fluid before it accumulates enough to cause you difficulty breathing. But if we remove the catheter now, the fluid will accumulate again and the problem will return. The catheter can come out when the two layers of the pleura have sealed against each other and there is no longer space for fluid to accumulate. What we are looking for to know that has happened is that the drainage volume falls consistently below 50 milliliters per session for three consecutive sessions. That tells us the pleura has closed. When that happens, we evaluate with imaging whether the space is sealed and if it is, the catheter comes out.)

What should thoracic oncology nurses tell Spanish-speaking patients about what happens after a Lung-RADS 4X PET-CT?

The post-PET-CT decision tree is information that Lung-RADS 4X patients need before the PET is done, not after, because the uncertainty between the screening result and the PET result is the most anxious period the patient will experience in the early diagnostic workup. Understanding the decision tree in advance gives the patient a framework that contains the anxiety rather than allowing it to grow unchecked. The four PET outcomes and their decision paths: first, if the nodule is PET-negative (SUVmax below 2.5, meaning the nodule is not taking up glucose at a rate consistent with malignancy), the recommendation is typically short-interval CT surveillance — a three-month chest CT to confirm stability — with the understanding that a negative PET substantially lowers the probability of malignancy, though it does not eliminate it in slow-growing cancers like well-differentiated adenocarcinoma in situ. Second, if the PET is indeterminate (mildly elevated SUVmax, 2.5 to 4.0), the recommendation is usually tissue sampling — either CT-guided needle biopsy or bronchoscopy with EBUS, depending on the location and size of the nodule — to obtain a definitive pathological diagnosis. Third, if the PET is positive (SUVmax above 4.0) with FDG uptake limited to the nodule, the staging workup proceeds: PET of the entire body to look for mediastinal involvement or distant metastases, and tissue sampling to confirm histology. Fourth, if the PET shows not only the nodule but also mediastinal nodes or distant uptake, the staging classification immediately moves toward locally advanced or metastatic disease and the multidisciplinary team meets to discuss treatment rather than surgical staging. The nurse explaining this in Spanish: “El PET nos va a dar una de varias respuestas. Si el nódulo no consume glucosa de manera anormal, el riesgo de que sea cáncer baja mucho y el próximo paso es una tomografía de seguimiento en tres meses para confirmar que el nódulo no está creciendo. Si el PET es positivo, eso significa que necesitamos más información — ya sea una biopsia del nódulo para saber exactamente qué tipo de células son, o una evaluación completa para ver si hay más actividad en otras partes del cuerpo. Voy a darle a usted el número del equipo de oncología para que pueda llamar en cuanto tenga el resultado del PET y le explicaremos exactamente qué significa y cuál es el próximo paso.” (The PET is going to give us one of several answers. If the nodule does not consume glucose in an abnormal way, the risk that it is cancer goes down significantly and the next step is a follow-up CT in three months to confirm the nodule is not growing. If the PET is positive, that means we need more information — either a biopsy of the nodule to know exactly what type of cells they are, or a complete evaluation to see if there is more activity in other parts of the body. I am going to give you the oncology team's number so you can call as soon as you have the PET result and we will explain exactly what it means and what the next step is.)

What are the most important Spanish phrases for thoracic oncology nurses?

Thoracic oncology nursing involves three recurring communication gaps with Spanish-speaking patients that directly affect how patients process diagnoses, participate in treatment decisions, and manage their disease at home. The first is the gap between a Lung-RADS screening result and the patient's interpretation of it: the patient who receives a 4X result without context concludes she has cancer, needs immediate surgery, and comes to the first appointment in a state of high anxiety that makes it almost impossible to absorb nuanced information about what happens next. The framing that opens the conversation is: “Lung-RADS 4X no es un diagnóstico de cáncer. Es una categoría que describe cómo se ve el nódulo en la imagen y recomienda el próximo paso, que es un PET-CT. Vamos a obtener esa respuesta antes de sacar conclusiones.” (Lung-RADS 4X is not a cancer diagnosis. It is a category that describes how the nodule looks on the image and recommends the next step, which is a PET-CT. We are going to get that answer before drawing conclusions.) The second is the gap between the surgeon's explanation of why stage IIIA NSCLC is not surgically treated and the family's interpretation of it as refusal or inadequacy: “El cirujano no dijo que no puede hacer la operación. Dijo que la operación no sería el tratamiento correcto para este tipo de cáncer en este estadio, porque el cáncer ya se extendió a los ganglios del mediastino y la cirugía dejaría esas células atrás. La quimioradioterapia llega a esos ganglios. La cirugía no puede.” (The surgeon did not say he cannot perform the operation. He said the operation would not be the correct treatment for this type of cancer at this stage, because the cancer has already spread to the mediastinal lymph nodes and surgery would leave those cells behind. Chemoradiation reaches those lymph nodes. Surgery cannot.) The third is the gap between the patient feeling better with a tunneled pleural catheter and the catheter being removable: “Usted se siente mejor porque el catéter está drenando el líquido. El líquido va a seguir produciéndose mientras la pleura esté afectada por el cáncer. El catéter puede salir cuando el drenaje baje de forma consistente por debajo de 50 mililitros por sesión durante tres sesiones seguidas — eso nos indica que las capas de la pleura se sellaron entre sí y ya no hay espacio para el líquido. No es que el catéter sale cuando usted se siente mejor. Sale cuando la imagen y el volumen de drenaje muestran que la pleura se cerró.” (You are feeling better because the catheter is draining the fluid. The fluid will continue to be produced as long as the pleura is affected by the cancer. The catheter can come out when the drainage consistently falls below 50 milliliters per session for three consecutive sessions — that tells us the pleural layers sealed against each other and there is no longer space for the fluid. It is not that the catheter comes out when you feel better. It comes out when the imaging and the drainage volume show the pleura has closed.)

July 24, 2026 · Clinical Spanish · Thoracic Oncology · Lung Cancer · Nurse Navigation

Spanish for thoracic oncology nurses — the patient whose Lung-RADS 4X result terrified her and who does not know what the score means, the patient with stage III NSCLC who was told surgery is not an option and cannot understand why, and the patient with a tunneled pleural catheter who is feeling better and cannot understand why the tube cannot come out

Camila Reyes is 58. She is a hotel front desk manager from San Antonio who has worked twelve-hour shifts standing at a registration counter for nineteen years. She is organized, direct, and comfortable under pressure — she handles overbookings, irate guests, and fire alarms with the same steadiness. She smoked for twenty-two years, a pack a day, and quit eight years ago at the age of fifty after her older sister was diagnosed with chronic obstructive pulmonary disease. Her primary care doctor enrolled her in the low-dose CT lung cancer screening program at her last annual visit, explaining that the guidelines recommend annual screening for people with her smoking history who quit within the last fifteen years.

She completed the CT scan eleven days ago. She checked the patient portal every morning for the result. It arrived on a Tuesday: a radiology report in English, five paragraphs long, ending with a Lung-RADS category designation she did not recognize and a recommendation for PET-CT within four weeks.

She typed “Lung-RADS 4X” into a search engine at 11 PM that night.

She arrived at the thoracic oncology clinic for her navigator intake appointment this morning having slept approximately six hours over three nights. On the intake form, under “what brings you here today,” she wrote: me dijeron que tengo cáncer de pulmón y necesito saber cuándo operan.

They told me I have lung cancer and I need to know when they operate.

The thoracic oncology nurse navigator who read the form recognized the trajectory immediately. She has seen this before — many times, every week.

What this post covers

This post covers three conversations that recur in thoracic oncology nursing when the patient speaks Spanish. The first is Camila’s — the patient who received a Lung-RADS 4X result from a low-dose CT screening scan, searched the score online without clinical context, concluded she has cancer and needs surgery, and arrived at the navigator appointment in a state of high anxiety that cannot absorb nuanced information until one specific frame is corrected. The second is Eduardo Vargas, 63, a retired postal worker from El Paso with a new diagnosis of stage IIIA non-small cell lung cancer with mediastinal nodal involvement, who was told by a thoracic surgeon that he is not a surgical candidate, and whose wife Carmen arrived at the thoracic oncology appointment furious and demanding a second opinion at a hospital that will actually operate. The third is Rosa Fuentes, 67, a retired hairdresser from Houston with malignant pleural effusion secondary to stage IVA lung cancer, who had a tunneled pleural catheter placed after her effusion recurred following thoracentesis, whose shortness of breath has improved dramatically with home drainage, and who cannot understand why a tube that appears to be solving the problem must stay in her chest indefinitely.

In each case the communication failure has the same underlying structure: the patient received clinical information without the conceptual framework needed to interpret it. Camila received a Lung-RADS category without knowing what the system is or what the category describes. Eduardo received a surgical recommendation against operating without understanding why the surgeon’s decision is clinically correct rather than professionally inadequate. Rosa received a catheter that improved her symptoms without understanding what the catheter is doing, why the underlying problem requires ongoing management, or what the criteria for removal actually are. The thoracic oncology nurse who provides that framework — in specific, accurate language, in Spanish — converts a frightened, resistant patient into one who can participate in a complex multidisciplinary treatment plan rather than fight it.

Scenario one: Camila and the Lung-RADS 4X she spent three nights googling

Thoracic oncology nurse navigator Marisol Cruz has worked in the lung cancer program for seven years. She came from general oncology and took the thoracic navigation position because she wanted to work in the early-detection space, the part of oncology where the clinical opportunity is largest. She has seen the Lung-RADS anxiety presentation dozens of times. She knows that the patient sitting across from her has built a complete narrative — cancer, surgery, chemotherapy, hair loss, disability — on the basis of a two-word search string that returned results optimized for maximum engagement rather than clinical accuracy.

She calls Camila from the waiting room. She sees the controlled tension in the way Camila sits, the way she keeps her phone in her hand. She brings her to the consultation room, closes the door, sits across the table rather than behind a desk, and reads the intake form.

Marisol: — Leo en la forma que escribió que le dijeron que tiene cáncer de pulmón. Quiero empezar ahí, porque lo que le voy a decir es importante: nadie le ha dicho eso. ¿Puedo preguntarle qué fue exactamente lo que recibió?

I read on the form that you wrote that they told you you have lung cancer. I want to start there, because what I am going to tell you is important: nobody has told you that. Can I ask you what exactly it was that you received?

Camila: — Recibí el resultado de la tomografía en el portal. Dice Lung-RADS 4X. Busqué eso en Google y sale que es altamente sospechoso de malignidad y que es cáncer hasta que se demuestre lo contrario. Eso fue lo que entendí.

I received the CT result in the portal. It says Lung-RADS 4X. I searched that on Google and it comes up that it is highly suspicious for malignancy and that it is cancer until proven otherwise. That is what I understood.

Marisol: — Entiendo por qué lo interpretó así. Voy a explicarle qué es Lung-RADS, porque sin esa explicación el resultado no tiene sentido. ¿Puedo hacer eso primero?

I understand why you interpreted it that way. I am going to explain what Lung-RADS is, because without that explanation the result does not make sense. Can I do that first?

Camila: — Sí.

Yes.

What Lung-RADS is and what a score describes

Marisol: — Lung-RADS es un sistema de reporte que los radiólogos usan para describir lo que ven en una tomografía de tórax de detección y para hacer una recomendación de cuál es el próximo paso. No es un diagnóstico. Es un lenguaje — una escala del 1 al 4 que describe las características de lo que se vio en la imagen y dice: basado en esas características, aquí es lo que recomendamos hacer a continuación.

Lung-RADS is a reporting system that radiologists use to describe what they see on a chest CT screening scan and to make a recommendation about what the next step is. It is not a diagnosis. It is a language — a scale from 1 to 4 that describes the characteristics of what was seen on the image and says: based on those characteristics, here is what we recommend doing next.

Camila: — ¿Y el 4 es lo más alto?

And 4 is the highest?

Marisol: — La categoría 4 en Lung-RADS describe hallazgos que se consideran altamente sospechosos — lo que significa que las características de la imagen son preocupantes y que el próximo paso necesita ser pronto y específico. La X después del 4 es un modificador que indica que el nódulo tiene alguna característica adicional — como márgenes espiculados, crecimiento reciente, o una combinación de vidrio esmerilado con componente sólido — que hace que el radiólogo quiera dar prioridad al estudio siguiente. Lung-RADS 4X dice: esto necesita evaluarse urgente con un PET-CT. No dice: usted tiene cáncer. Dice: la imagen es lo suficientemente sospechosa como para que el próximo estudio sea inmediato en lugar de diferido.

Category 4 in Lung-RADS describes findings that are considered highly suspicious — which means that the imaging characteristics are concerning and that the next step needs to be soon and specific. The X after the 4 is a modifier that indicates the nodule has some additional characteristic — such as spiculated margins, recent growth, or a combination of ground-glass opacity with a solid component — that makes the radiologist want to prioritize the next study. Lung-RADS 4X says: this needs to be evaluated urgently with a PET-CT. It does not say: you have cancer. It says: the image is suspicious enough that the next study should be immediate rather than deferred.

Camila is quiet for a moment. Her grip on the phone has loosened slightly.

Camila: — ¿Y el PET-CT es para saber si es cáncer?

And the PET-CT is to find out if it is cancer?

Marisol: — El PET-CT es el siguiente paso en una serie de pasos. Lo que hace es medir si el nódulo está consumiendo glucosa de manera anormal — los tumores malignos tienen un metabolismo muy activo y absorben glucosa mucho más rápido que el tejido normal. Si el nódulo no consume glucosa de manera anormal, eso reduce significativamente la probabilidad de que sea cáncer, aunque no la elimina completamente. Muchos nódulos con características que parecen sospechosas en la tomografía resultan ser benignos en el PET. Una cicatriz antigua, un granuloma de una infección antigua, un ganglio linfático reactivo — todas estas cosas pueden tener características que llaman la atención en la tomografía y resultan ser benignas cuando se les hace el PET. Usted no sabe todavía qué tiene. Eso es lo que el PET nos va a ayudar a determinar.

The PET-CT is the next step in a series of steps. What it does is measure whether the nodule is consuming glucose abnormally — malignant tumors have a very active metabolism and absorb glucose much faster than normal tissue. If the nodule does not consume glucose abnormally, that significantly reduces the probability that it is cancer, although it does not eliminate it completely. Many nodules with characteristics that appear suspicious on CT turn out to be benign on PET. An old scar, a granuloma from an old infection, a reactive lymph node — all of these things can have characteristics that attract attention on CT and turn out to be benign when the PET is done. You do not know yet what you have. That is what the PET is going to help us determine.

What happens after the PET and why the pathway exists

Camila: — ¿Y si el PET sale positivo?

And if the PET comes back positive?

Marisol: — Si el PET muestra actividad metabólica en el nódulo, el próximo paso es obtener tejido — una biopsia — para saber exactamente qué tipo de células son. No podemos llamarlo cáncer hasta que tengamos el tejido. El PET nos dice que algo está consumiendo glucosa de manera anormal. La biopsia nos dice qué es. Dependiendo de dónde está el nódulo y qué tan accesible es, la biopsia puede ser una aguja guiada por tomografía desde afuera del tórax, o puede ser una broncoscopia desde adentro de los bronquios. Si la biopsia confirma cáncer, entonces tenemos el tipo histológico — qué tipo de células son — y podemos hacer las pruebas moleculares que determinan el tratamiento más específico para ese tipo de cáncer. Si la biopsia confirma que no es cáncer, cerramos ese capítulo con seguimiento apropiado.

If the PET shows metabolic activity in the nodule, the next step is to obtain tissue — a biopsy — to know exactly what type of cells they are. We cannot call it cancer until we have the tissue. The PET tells us something is consuming glucose abnormally. The biopsy tells us what it is. Depending on where the nodule is and how accessible it is, the biopsy can be a needle guided by CT from outside the chest, or it can be a bronchoscopy from inside the bronchi. If the biopsy confirms cancer, then we have the histological type — what type of cells they are — and we can do the molecular tests that determine the most specific treatment for that type of cancer. If the biopsy confirms it is not cancer, we close that chapter with appropriate follow-up.

Camila: — ¿Cuántos pasos hay todavía antes de que sepamos si tengo cáncer?

How many steps are there still before we know if I have cancer?

Marisol: — Uno seguro, y posiblemente dos. El PET es el primero. Si el PET es negativo, seguimos con tomografía en tres meses. Si el PET es positivo, el segundo paso es la biopsia. Después de la biopsia, sabemos. Yo soy su navegadora durante todo ese proceso — es mi trabajo llamarle cuando llega cada resultado, explicarle qué significa, y decirle cuál es el próximo paso antes de que usted tenga tiempo de buscar en Google y llegar a una conclusión que no tiene información suficiente para sostener.

One for certain, and possibly two. The PET is the first. If the PET is negative, we continue with CT in three months. If the PET is positive, the second step is the biopsy. After the biopsy, we know. I am your navigator throughout that entire process — it is my job to call you when each result comes in, to explain what it means, and to tell you what the next step is before you have time to search on Google and reach a conclusion that does not have enough information to sustain it.

Camila: — Si alguien me hubiera explicado eso cuando llegó el resultado, no habría pasado tres noches sin dormir.

If someone had explained that to me when the result came in, I would not have spent three nights without sleep.

Marisol: — Ese es exactamente el problema que mi rol existe para resolver. A partir de ahora, cuando llega un resultado, lo primero que recibe no es el portal — soy yo llamándole para explicarle qué significa.

That is exactly the problem my role exists to resolve. From now on, when a result comes in, the first thing you receive is not the portal — it is me calling you to explain what it means.

They schedule the PET-CT for three days later. Marisol gives Camila her direct line and tells her to call if she receives any result notification from the portal before Marisol calls her first.

Scenario two: Eduardo and the surgery no one will explain

Eduardo Vargas is 63. He is a retired postal worker from El Paso who spent thirty-four years delivering mail on a route that covered eleven miles of walking per shift. He developed a cough in January that he attributed to seasonal allergies. His wife Carmen pushed him to see the doctor in March when she heard him coughing in the night. A chest X-ray showed a hilar mass. The CT confirmed a 3.8-centimeter spiculated adenocarcinoma in the right upper lobe with ipsilateral mediastinal lymphadenopathy. The PET was positive in the primary lesion and in multiple mediastinal and subcarinal nodes. An endobronchial ultrasound-guided procedure confirmed N2 nodal involvement by pathology: adenocarcinoma in stations 4R and 7.

The thoracic surgery team saw him three weeks ago. The attending explained that based on the nodal involvement, he was not a surgical candidate and that the appropriate treatment was concurrent chemoradiation. He was referred to thoracic oncology.

Carmen has not accepted this. She has spent the past three weeks researching second opinions. She has called three other institutions. She arrived at the thoracic oncology appointment forty-five minutes early with a printed packet of research and a list of questions that begins with: ¿por qué los cirujanos de este hospital no operan el cáncer de mi esposo?

Why do the surgeons at this hospital not operate on my husband’s cancer?

Eduardo sits quietly in the chair next to her. He has the look of a man who has been in many meetings in the past three weeks where he was the subject rather than the participant.

The staging system and what N2 means

Thoracic oncology nurse Daniela Ramos has worked in this clinic for nine years. She has had the stage III surgical candidacy conversation many times. She knows that the family’s anger is not personal and is not irrational — it is the correct emotional response to an explanation that was given without sufficient context to make the recommendation understandable. She begins with Eduardo, not Carmen.

Daniela: — Eduardo, quiero empezar con usted. ¿Cuál es la parte que menos entiende de lo que le han dicho hasta ahora?

Eduardo, I want to start with you. What is the part that you understand least of what they have told you so far?

Eduardo: — No entiendo por qué si tengo un tumor en el pulmón, la solución no es sacarlo. Eso es lo que no entiendo. El tumor está ahí. ¿Por qué no lo quitan?

I do not understand why if I have a tumor in the lung, the solution is not to remove it. That is what I do not understand. The tumor is there. Why do they not remove it?

Daniela: — Eso es exactamente lo que quiero explicarle. Y la respuesta no es que los cirujanos no pueden hacerlo técnicamente. Es algo más importante que eso. ¿Puedo explicarle el sistema de estadificación primero? Porque sin eso la respuesta no tiene sentido.

That is exactly what I want to explain to you. And the answer is not that the surgeons cannot do it technically. It is something more important than that. Can I explain the staging system first? Because without that the answer does not make sense.

Eduardo: — Sí.

Yes.

Daniela: — El cáncer de pulmón tiene cuatro estadios. El estadio 1 y el estadio 2 son cánceres que están en el pulmón, localizados. El estadio 1 es el tumor solo, sin propagación a los ganglios linfáticos. El estadio 2 es el tumor con propagación a los ganglios linfáticos dentro del mismo pulmón. En esos dos estadios, la cirugía — quitar el lóbulo del pulmón donde está el tumor — es el tratamiento principal y puede ser curativa. El estadio 3 es diferente. El estadio 3 significa que el cáncer se ha extendido a los ganglios linfáticos del mediastino — el espacio entre los dos pulmones, donde están los ganglios centrales del sistema linfático del tórax. El estadio 3 no es que el tumor creció más. Es que el cáncer ya demostró que puede moverse más allá del pulmón.

Lung cancer has four stages. Stage 1 and stage 2 are cancers that are in the lung, localized. Stage 1 is the tumor alone, without spread to the lymph nodes. Stage 2 is the tumor with spread to the lymph nodes within the same lung. In those two stages, surgery — removing the lobe of the lung where the tumor is — is the main treatment and can be curative. Stage 3 is different. Stage 3 means the cancer has spread to the lymph nodes of the mediastinum — the space between the two lungs, where the central lymph nodes of the thoracic lymphatic system are located. Stage 3 is not that the tumor grew larger. It is that the cancer has already demonstrated it can travel beyond the lung.

Carmen: — Pero si quitan el pulmón y los ganglios al mismo tiempo, ¿no queda todo?

But if they remove the lung and the lymph nodes at the same time, would that not get everything?

Why surgery does not control N2 disease

Daniela: — Carmen, esa es exactamente la pregunta correcta. Y la respuesta es la razón por la que la cirugía no es el tratamiento correcto para el estadio 3. Los ganglios del mediastino no son los únicos ganglios que reciben drenaje linfático del área del tumor de Eduardo. Cuando el cáncer se ha extendido a los ganglios del mediastino, eso significa que ha viajado por los vasos linfáticos desde el pulmón hasta el mediastino. El problema es que ese mismo sistema linfático continúa — más allá del mediastino, hacia el resto del cuerpo. Cuando los ganglios mediastinales están involucrados, hay células cancerosas microscópicas en esa red linfática que no son visibles en ningún estudio de imagen. La cirugía quita lo que se puede ver y tocar. No puede quitar lo que no se puede ver. Si quitamos el lóbulo del pulmón y los ganglios que podemos ver, dejamos atrás una red de células microscópicas que van a recidivar — y el paciente ha pasado por una cirugía mayor con sus propios riesgos, recuperación larga, y pérdida de capacidad pulmonar, sin haber controlado la enfermedad.

Carmen, that is exactly the right question. And the answer is the reason why surgery is not the correct treatment for stage 3. The mediastinal lymph nodes are not the only lymph nodes that receive lymphatic drainage from the area of Eduardo’s tumor. When cancer has spread to the mediastinal lymph nodes, it means it has traveled through the lymphatic vessels from the lung to the mediastinum. The problem is that the same lymphatic system continues — beyond the mediastinum, toward the rest of the body. When the mediastinal nodes are involved, there are microscopic cancer cells in that lymphatic network that are not visible on any imaging study. Surgery removes what can be seen and touched. It cannot remove what cannot be seen. If we remove the lung lobe and the nodes that are visible, we leave behind a network of microscopic cells that are going to recur — and the patient has gone through major surgery with its own risks, long recovery, and loss of pulmonary capacity, without having controlled the disease.

Carmen is quiet. She looks at the printed packet in her lap.

Carmen: — ¿Y los otros hospitales que llamé?

And the other hospitals I called?

Daniela: — Si recibe una segunda opinión de un centro oncológico especializado en cáncer de pulmón — un centro de referencia — le van a decir lo mismo. El estadio 3A con involucro de ganglios N2 no se opera. Eso no es una política de este hospital. Es el estándar de tratamiento basado en los ensayos clínicos que compararon cirugía con quimioradioterapia en este estadio. La cirugía no mejoró los resultados en comparación con la quimioradioterapia concurrente — y añadió la morbilidad de la operación. Buscar un hospital que opere no va a encontrar un centro que tenga mejores resultados. Va a encontrar un centro que no aplica el estándar de cuidado basado en evidencia.

If you get a second opinion from an oncology center specialized in lung cancer — a referral center — they are going to tell you the same thing. Stage 3A with N2 nodal involvement is not operated on. That is not a policy of this hospital. It is the treatment standard based on the clinical trials that compared surgery with chemoradiation in this stage. Surgery did not improve outcomes compared to concurrent chemoradiation — and it added the morbidity of the operation. Looking for a hospital that will operate is not going to find a center with better outcomes. It will find a center that does not apply the evidence-based standard of care.

Carmen looks at Eduardo. Eduardo looks at Daniela.

Eduardo: — Entonces cuando el cirujano dijo que no era candidato, no quiso decir que somos un caso perdido.

So when the surgeon said I was not a candidate, he did not mean we are a lost cause.

Daniela: — No. Quiso decir que la cirugía no es el tratamiento correcto para su estadio, y que el tratamiento correcto es la quimioradioterapia concurrente. El estadio 3A no resecable, tratado con quimioradioterapia y después inmunoterapia de consolidación, tiene tasas de supervivencia a cinco años de 15 a 35%, con algunos centros reportando resultados mejores en pacientes bien seleccionados. No es lo mismo que el estadio 1 o 2, pero tampoco es lo que muchas familias imaginan cuando escuchan que la cirugía no está en la tabla.

No. He meant that surgery is not the correct treatment for your stage, and that the correct treatment is concurrent chemoradiation. Stage 3A non-resectable, treated with chemoradiation and then consolidation immunotherapy, has five-year survival rates of 15 to 35%, with some centers reporting better outcomes in well-selected patients. It is not the same as stage 1 or 2, but it is also not what many families imagine when they hear that surgery is not on the table.

What concurrent chemoradiation and durvalumab consolidation mean

Eduardo: — ¿Y qué es lo que van a hacer exactamente?

And what exactly are they going to do?

Daniela: — El tratamiento tiene dos fases. La primera fase es quimioradioterapia concurrente — quimioterapia y radioterapia al mismo tiempo — durante aproximadamente seis semanas. La quimioterapia que probablemente van a usar es cisplatino y etopósido. Lo que hace la quimioterapia en este contexto son dos cosas: sensitiza las células del cáncer a la radioterapia, haciéndolas más vulnerables a la radiación, y trata la enfermedad microscópica que pudiera haber viajado más allá del tórax. La radioterapia — que se entrega con mucha precisión, apuntando al tumor y a los ganglios del mediastino al mismo tiempo — mata las células del tumor dentro del tórax. Las dos cosas juntas son más efectivas que cualquiera de las dos solas.

The treatment has two phases. The first phase is concurrent chemoradiation — chemotherapy and radiation at the same time — for approximately six weeks. The chemotherapy they will most likely use is cisplatin and etoposide. What the chemotherapy does in this context is two things: it sensitizes the cancer cells to the radiation, making them more vulnerable to it, and it treats microscopic disease that may have traveled beyond the chest. The radiation — which is delivered with great precision, targeting the tumor and the mediastinal lymph nodes at the same time — kills the tumor cells within the chest. Both things together are more effective than either one alone.

Eduardo: — ¿Y después de las seis semanas?

And after the six weeks?

Daniela: — Si el tumor respondió y usted toleró bien el tratamiento, la segunda fase es inmunoterapia de consolidación con un medicamento que se llama durvalumab. Es una inmunoterapia — no es quimioterapia clásica — que bloquea una proteína que los tumores usan para esconderse del sistema inmune. Se da como infusión intravenosa cada cuatro semanas, durante hasta un año. Los ensayos clínicos mostraron que agregar durvalumab después de la quimioradioterapia en estadio 3 mejora la supervivencia libre de progresión — el tiempo que pasa antes de que la enfermedad avance — de manera significativa.

If the tumor responded and you tolerated the treatment well, the second phase is consolidation immunotherapy with a medication called durvalumab. It is an immunotherapy — it is not classic chemotherapy — that blocks a protein that tumors use to hide from the immune system. It is given as an intravenous infusion every four weeks, for up to one year. The clinical trials showed that adding durvalumab after chemoradiation in stage 3 improves progression-free survival — the time that passes before the disease advances — significantly.

Carmen: — ¿Entonces hay un plan?

So there is a plan?

Daniela: — Hay un plan. Un plan basado en los mejores datos que tenemos para este tipo de cáncer en este estadio. La cirugía no es el plan correcto para el estadio 3A de Eduardo, y entiendo que eso fue difícil de escuchar la primera vez. Pero la quimioradioterapia y la inmunoterapia no son el plan de segunda opción. Son el plan de primera opción — el tratamiento que da los mejores resultados para la enfermedad que Eduardo tiene.

There is a plan. A plan based on the best data we have for this type of cancer at this stage. Surgery is not the correct plan for Eduardo’s stage 3A, and I understand that was difficult to hear the first time. But chemoradiation and immunotherapy are not the second-best plan. They are the first-best plan — the treatment that gives the best outcomes for the disease Eduardo has.

Carmen puts the printed packet on the table.

Eduardo: — Nadie lo había explicado así. Solo me dijeron que no era candidato para cirugía y me mandaron aquí. No supe hasta ahora por qué.

Nobody had explained it that way. They just told me I was not a surgical candidate and sent me here. I did not know until now why.

Daniela: — Eso es lo que esta cita existe para hacer.

That is what this appointment exists to do.

Scenario three: Rosa and the catheter she wants out

Rosa Fuentes is 67. She is a retired hairdresser from Houston who spent forty-one years on her feet at the salon, listening to people, cutting their hair, following families across decades. She was diagnosed with stage IVA non-small cell lung cancer — squamous cell carcinoma — fourteen months ago after presenting with progressive dyspnea and a right-sided pleural effusion on her first chest X-ray. She has been receiving carboplatin-based chemotherapy with a programmed death-ligand 1 checkpoint inhibitor. Her tumor has had a partial response. Her pleural disease has continued.

The effusion was first drained by therapeutic thoracentesis six months ago: 1,200 mL. It recurred at three weeks. A second thoracentesis removed 1,800 mL. It recurred at two weeks. The interventional pulmonology team placed a tunneled pleural catheter — a PleurX catheter — four weeks ago. Rosa drains it at home three times per week: Monday, Wednesday, Friday. She drains between 200 and 300 mL per session. Her dyspnea at rest has resolved. She walks to the end of the block without needing to stop.

Her daughter Maria has been present at every clinic visit since the catheter was placed. At the first visit she asked whether the catheter would come out soon. At the second visit she asked again. At this visit she asks before Daniela has finished reading the chart:

Maria: — ¿Hoy puede salir el catéter? Mamá se siente mucho mejor. El volumen que drena está bajando. Ella va a cumplir 68 años el mes que viene y no quiere tener ese tubo en su cumpleaños.

Can the catheter come out today? Mom is feeling much better. The volume she is draining is going down. She is going to turn 68 next month and she does not want to have that tube on her birthday.

Rosa: — Me duele cuando hago el drenaje. Y el sitio de entrada se ve diferente a cuando lo pusieron. No me quejo — sé que me ayuda. Pero si hay una manera de quitarlo, prefiero quitarlo.

It hurts when I do the drainage. And the entry site looks different from when they placed it. I am not complaining — I know it helps me. But if there is a way to remove it, I prefer to remove it.

Why the effusion keeps coming back and what the catheter is managing

Thoracic oncology nurse Carmen Delgado has cared for Rosa across both of her thoracenteses and the catheter placement. She has had this conversation before. She knows that the patient who feels better with a catheter but does not understand why the catheter must stay will be tempted to drain less frequently, skip sessions when it seems like less is coming out, and ask at every appointment when removal is possible — and that a patient who drains less consistently reduces the chance of the spontaneous pleurodesis that is the only path to removal.

Carmen sits next to Rosa rather than across from her.

Carmen: — Rosa, quiero explicarle dos cosas. La primera es por qué el líquido sigue volviendo. La segunda es exactamente cuándo el catéter puede salir — no en términos generales, sino la condición específica que buscamos. ¿Está bien?

Rosa, I want to explain two things. The first is why the fluid keeps coming back. The second is exactly when the catheter can come out — not in general terms, but the specific condition we are looking for. Is that all right?

Rosa: — Sí.

Yes.

Carmen: — El derrame pleural que usted tiene se llama derrame maligno. La pleura — la membrana que cubre los pulmones y el interior del tórax — tiene dos capas, como dos hojas de papel con una pequeña cantidad de líquido entre ellas que las lubrica. En condiciones normales, esa pequeña cantidad de líquido se mantiene estable porque la producción y la absorción están en equilibrio. Cuando el cáncer involucra la pleura — ya sea porque células cancerosas están ahí directamente o porque el cáncer produce señales inflamatorias que afectan la membrana — la producción de líquido aumenta más rápido de lo que la pleura puede absorber. El resultado es que el líquido se acumula. El problema no es que el líquido vuelve cuando lo drenamos. El problema es que la causa de que el líquido se produzca — el cáncer que involucra la pleura — no para cuando drenamos.

The pleural effusion you have is called a malignant effusion. The pleura — the membrane that covers the lungs and the inside of the chest — has two layers, like two sheets of paper with a small amount of fluid between them that lubricates them. Under normal conditions, that small amount of fluid stays stable because production and absorption are in balance. When cancer involves the pleura — either because cancer cells are there directly or because the cancer produces inflammatory signals that affect the membrane — fluid production increases faster than the pleura can absorb. The result is that fluid accumulates. The problem is not that the fluid returns when we drain it. The problem is that the cause of the fluid being produced — the cancer involving the pleura — does not stop when we drain.

Maria: — ¿Pero la quimioterapia no está reduciendo el cáncer?

But is the chemotherapy not reducing the cancer?

Carmen: — La quimioterapia está teniendo una respuesta parcial — el tumor primario y algunos sitios han reducido. La enfermedad pleural es a veces más resistente a la quimioterapia sistémica que el tumor primario. Por ahora, la pleura sigue produciendo líquido a pesar de la quimioterapia. El catéter es el tratamiento que controla ese síntoma mientras la quimioterapia continúa. Usted se siente mejor no porque el problema de la pleura se resolvió, sino porque el catéter está drenando el líquido antes de que se acumule lo suficiente para causarle dificultad para respirar.

The chemotherapy is having a partial response — the primary tumor and some sites have reduced. Pleural disease is sometimes more resistant to systemic chemotherapy than the primary tumor. For now, the pleura continues to produce fluid despite the chemotherapy. The catheter is the treatment that manages that symptom while the chemotherapy continues. You are feeling better not because the pleural problem resolved, but because the catheter is draining the fluid before it accumulates enough to cause you difficulty breathing.

Rosa: — Entonces si quitamos el catéter ahora, ¿el líquido vuelve?

So if we remove the catheter now, the fluid comes back?

Carmen: — Sí. Si quitamos el catéter ahora, en dos o tres semanas el líquido se va a haber acumulado de nuevo al punto en que sentiría la dificultad para respirar que tenía antes. Y tendríamos que volver a poner el catéter — o hacer otra toracentesis, que es lo que estábamos haciendo antes del catéter, y que como usted sabe requería volver al hospital cada dos semanas.

Yes. If we remove the catheter now, in two to three weeks the fluid will have accumulated again to the point where you would feel the difficulty breathing that you had before. And we would need to put the catheter back in — or do another thoracentesis, which is what we were doing before the catheter, and which as you know required returning to the hospital every two weeks.

Pleurodesis and the conditions for removal

Maria: — Entonces, ¿nunca va a salir?

So it is never going to come out?

Carmen: — Puede salir. Hay una condición específica bajo la cual el catéter puede quitarse, y le voy a decir exactamente cuál es. Se llama pleurodesis — es cuando las dos capas de la pleura se adhieren entre sí y el espacio entre ellas se sella de manera permanente, de modo que ya no hay espacio para que el líquido se acumule. Esto puede ocurrir espontáneamente — sin que hagamos nada para provocarlo — cuando el catéter drena el líquido de manera consistente y mantiene las dos capas de la pleura en contacto durante suficiente tiempo. La inflamación que causa el propio catéter, combinada con el drenaje frecuente que mantiene la pleura seca, puede crear suficiente cicatriz para sellar el espacio.

It can come out. There is a specific condition under which the catheter can be removed, and I am going to tell you exactly what it is. It is called pleurodesis — it is when the two layers of the pleura adhere to each other and the space between them seals permanently, so that there is no longer space for fluid to accumulate. This can happen spontaneously — without us doing anything to cause it — when the catheter drains the fluid consistently and keeps the two layers of the pleura in contact for enough time. The inflammation caused by the catheter itself, combined with frequent drainage that keeps the pleura dry, can create enough scarring to seal the space.

Rosa: — ¿Y cómo sabemos si eso ocurrió?

And how do we know if that happened?

Carmen: — Lo que buscamos es que el volumen de drenaje baje de manera consistente por debajo de 50 mililitros por sesión — no en una sesión, sino en tres sesiones consecutivas. Cuando drena menos de 50 mililitros durante tres drenajes seguidos, eso nos indica que ya no hay líquido acumulándose en la pleura, lo que podría significar que el espacio se selló. En ese punto, pedimos una tomografía para confirmar si el espacio pleural está cerrado. Si la imagen confirma la pleurodesis, el catéter sale — en una visita de clínica, sin hospitalización, en aproximadamente quince minutos.

What we look for is that the drainage volume consistently falls below 50 milliliters per session — not in one session, but in three consecutive sessions. When you drain less than 50 milliliters for three drainage sessions in a row, that tells us there is no longer fluid accumulating in the pleura, which could mean the space has sealed. At that point, we order a CT to confirm whether the pleural space is closed. If the imaging confirms pleurodesis, the catheter comes out — in a clinic visit, without hospitalization, in approximately fifteen minutes.

Maria is writing this down.

Maria: — Entonces necesitamos que salga menos de 50 mililitros tres veces seguidas.

So we need less than 50 milliliters three times in a row.

Carmen: — Eso es exactamente lo que buscan. Y lo que hace que eso sea más probable es drenar con regularidad — tres veces por semana, sin saltarse sesiones, porque mantener la pleura seca de manera consistente es lo que da la mejor oportunidad de que las capas se adhieran. Saltarse sesiones de drenaje aumenta el líquido entre las capas y hace más difícil que se sellen.

That is exactly what you are looking for. And what makes that more likely is draining regularly — three times per week, without skipping sessions, because keeping the pleura consistently dry is what gives the best chance for the layers to adhere. Skipping drainage sessions increases the fluid between the layers and makes it harder for them to seal.

Rosa: — Entonces la mejor forma de que salga el catéter es seguir drenando.

So the best way to get the catheter out is to keep draining.

Carmen: — Exactamente eso. El catéter no sale por no necesitar más drenaje. Sale cuando el espacio se selló — y la manera de facilitar que se selle es drenando con regularidad. Rosa, ¿actualmente cuánto está drenando en cada sesión?

Exactly that. The catheter does not come out by no longer needing to drain. It comes out when the space has sealed — and the way to facilitate the sealing is by draining regularly. Rosa, how much are you currently draining in each session?

Rosa: — Los últimos tres drenajes salieron 280, 240, y 220. Antes salía más.

The last three drainages produced 280, 240, and 220. Before it was more.

Carmen: — Eso es una buena señal — el volumen está bajando, lo que sugiere que la pleura puede estar respondiendo. No estamos en los 50 mililitros todavía, pero la trayectoria es positiva. Sigamos drenando tres veces por semana y revisamos en cuatro semanas. Si para entonces estamos consistentemente por debajo de 150 mililitros, la pleurodesis espontánea puede estar ocurriendo.

That is a good sign — the volume is going down, which suggests the pleura may be responding. We are not at the 50 milliliters yet, but the trajectory is positive. Let us continue draining three times per week and check in four weeks. If by then we are consistently below 150 milliliters, spontaneous pleurodesis may be occurring.

Rosa: — Y si para mi cumpleaños estamos en 50, ¿lo quitamos?

And if by my birthday we are at 50, do we remove it?

Carmen: — Si para su cumpleaños estamos en tres sesiones seguidas de menos de 50 mililitros, pedimos la tomografía ese día.

If by your birthday we are at three consecutive sessions of less than 50 milliliters, we order the CT that day.

Rosa smiles for the first time in the appointment.

Maria writes “50 mL x 3” at the top of her notepad and underlines it twice.

Eight practical phrases for thoracic oncology nurses

These are the phrases that recur in thoracic oncology nursing when the patient speaks Spanish. Each one addresses a communication gap that directly affects how the patient processes a diagnosis, participates in treatment, or manages a chronic intervention at home.

1. Lung-RADS is not a cancer diagnosis — it describes imaging characteristics and recommends next steps

Lung-RADS no es un diagnóstico. Es una categoría que describe cómo se ve el nódulo en la imagen y recomienda el próximo paso. Lung-RADS 4X significa que las características de la imagen son altamente sospechosas y que el próximo estudio — el PET-CT — necesita hacerse urgente. No dice que usted tiene cáncer. Dice que necesitamos el PET ahora.

Lung-RADS is not a diagnosis. It is a category that describes how the nodule looks on the image and recommends the next step. Lung-RADS 4X means that the imaging characteristics are highly suspicious and that the next study — the PET-CT — needs to happen urgently. It does not say you have cancer. It says we need the PET now.

2. The PET-CT determines metabolic activity, not the final diagnosis

El PET mide si el nódulo está consumiendo glucosa de manera anormal — que es lo que los tumores malignos hacen. Si el PET es negativo, el riesgo de cáncer baja mucho. Si es positivo, el próximo paso es la biopsia para saber exactamente qué son las células. El PET no es el diagnóstico final — es el siguiente paso para acercarnos a él.

The PET measures whether the nodule is consuming glucose abnormally — which is what malignant tumors do. If the PET is negative, the risk of cancer goes down significantly. If it is positive, the next step is the biopsy to know exactly what the cells are. The PET is not the final diagnosis — it is the next step toward it.

3. Stage IIIA NSCLC is not resectable because surgery cannot reach microscopic nodal disease

La cirugía quita lo que puede ver y tocar. En el estadio 3A, el cáncer ya está en los ganglios del mediastino y en los vasos linfáticos que los conectan. Esas células microscópicas no son visibles en la imagen y la cirugía no puede alcanzarlas. Quitar el tumor primario dejaría la enfermedad mediastinal atrás, y eso no controla el cáncer.

Surgery removes what it can see and touch. In stage 3A, the cancer is already in the mediastinal lymph nodes and in the lymphatic vessels connecting them. Those microscopic cells are not visible on imaging and surgery cannot reach them. Removing the primary tumor would leave the mediastinal disease behind, and that does not control the cancer.

4. Concurrent chemoradiation is the first-line treatment for stage IIIA, not a fallback

La quimioradioterapia concurrente no es el plan de segunda opción cuando la cirugía no está disponible. Es el tratamiento de primera línea basado en ensayos clínicos para el estadio 3A. La quimioterapia sensitiza las células al daño de la radiación y trata la enfermedad sistémica. La radiación trata el tumor y los ganglios mediastinales al mismo tiempo. Juntos son más efectivos que cualquiera de los dos solos.

Concurrent chemoradiation is not the second-best plan when surgery is not available. It is the first-line treatment based on clinical trials for stage 3A. The chemotherapy sensitizes cells to radiation damage and treats systemic disease. The radiation treats the tumor and the mediastinal nodes simultaneously. Together they are more effective than either alone.

5. Durvalumab consolidation continues controlling the cancer after chemoradiation

Después de la quimioradioterapia, durvalumab es una inmunoterapia que bloquea la proteína que los tumores usan para esconderse del sistema inmune. Se da cada cuatro semanas durante hasta un año. El ensayo PACIFIC mostró que durvalumab después de quimioradioterapia en estadio 3 mejora significativamente el tiempo antes de que la enfermedad avance.

After chemoradiation, durvalumab is an immunotherapy that blocks the protein tumors use to hide from the immune system. It is given every four weeks for up to one year. The PACIFIC trial showed that durvalumab after chemoradiation in stage 3 significantly improves the time before disease progression.

6. Malignant pleural effusion recurs because the pleura continues to produce fluid as long as cancer involves it

El derrame maligno vuelve porque el cáncer que involucra la pleura produce señales que aumentan la producción de líquido más rápido de lo que la pleura puede absorber. Drenar el líquido no trata la causa — trata el síntoma. La causa es la enfermedad pleural, que la quimioterapia trata pero no necesariamente elimina de manera completa ni rápida.

The malignant effusion comes back because the cancer involving the pleura produces signals that increase fluid production faster than the pleura can absorb it. Draining the fluid does not treat the cause — it treats the symptom. The cause is the pleural disease, which the chemotherapy treats but does not necessarily eliminate completely or quickly.

7. The tunneled pleural catheter can be removed when drainage consistently falls below 50 mL per session for three sessions

El catéter puede salir cuando las dos capas de la pleura se adhirieron entre sí — pleurodesis espontánea — y ya no hay espacio para el líquido. La señal que buscamos: volumen de drenaje consistentemente por debajo de 50 mililitros por sesión durante tres sesiones consecutivas. Después de eso, tomografía para confirmar, y si está sellada, el catéter sale en la clínica en 15 minutos.

The catheter can come out when the two layers of the pleura have adhered to each other — spontaneous pleurodesis — and there is no longer space for the fluid. The signal we look for: drainage volume consistently below 50 milliliters per session for three consecutive sessions. After that, CT to confirm, and if sealed, the catheter comes out in the clinic in 15 minutes.

8. Regular drainage facilitates pleurodesis — the path out of the catheter is through consistent use of it

Drenar de manera consistente — tres veces por semana, sin saltarse sesiones — mantiene las capas de la pleura en contacto y da la mejor oportunidad de que se sellen. Saltarse sesiones aumenta el líquido entre las capas y hace más difícil la pleurodesis. La manera de facilitar que salga el catéter es usarlo con regularidad.

Draining consistently — three times per week, without skipping sessions — keeps the pleural layers in contact and gives the best chance of them sealing. Skipping sessions increases the fluid between the layers and makes pleurodesis less likely. The way to facilitate catheter removal is to use it regularly.

Why these three conversations share the same underlying structure

Camila, Eduardo, and Rosa arrived at the thoracic oncology clinic in very different states — Camila in acute anxiety over a screening result, Eduardo in confusion over a surgical recommendation his family cannot accept, Rosa in frustration over an intervention she cannot remove. But the communication failure that created each of their situations is structurally the same: they received an accurate procedural description without the conceptual framework needed to interpret it.

Camila received a Lung-RADS score without knowing what the scoring system is. Eduardo received a surgical recommendation against operating without understanding why the surgeon’s decision is clinically superior to operating. Rosa received a catheter that controls her symptoms without understanding what the catheter is managing, why the management must continue, or what the specific, measurable criteria for removal are.

In each case, the clinical team that provided the initial information was accurate. The Lung-RADS result was correctly classified. The surgical recommendation was correct for Eduardo’s stage. The catheter was correctly placed and functioning well. The information gap was not in the clinical decision — it was in the transfer of the framework the patient needed to integrate that decision into her understanding of her own situation.

The thoracic oncology nurse who closes that gap does not change the clinical facts. She translates them into a form the patient can use. Camila leaves the navigator appointment knowing what Lung-RADS is, what her next step is, and that she has a person to call when the PET result arrives before she has time to search for it. Eduardo and Carmen leave the thoracic oncology appointment understanding why surgery is not the correct treatment and what the treatment they have been offered is actually capable of achieving. Rosa leaves with a specific number — 50 milliliters, three sessions in a row — that converts an indefinite “until it improves” into a measurable target she can work toward every Monday, Wednesday, and Friday.

The clinical Spanish required for these conversations is not vocabulary. It is mechanism. Camila does not need the word for lymph node or for PET scanner. She needs to hear that Lung-RADS 4X is not a cancer diagnosis in language she can repeat to her husband that night. Eduardo does not need staging jargon. He needs to understand in plain Spanish why the surgeon’s recommendation was the right one. Rosa does not need a pharmacology lecture on pleurodesis. She needs fifty milliliters and three consecutive sessions and the understanding of why consistent drainage is what gets her to that number.

Those are the phrases that clinical Spanish for thoracic oncology nurses must carry. Everything else — the anatomy, the staging system, the mechanism of pleurodesis — is the scaffold that makes the phrases make sense.

Practice these conversations

ClinicaLingo’s scenario library includes roleplay practice for thoracic oncology conversations with Spanish-speaking patients, covering Lung-RADS screening result navigation, staging and surgical candidacy discussions, and malignant pleural effusion management. The AI roleplay tool lets you practice these conversations before they happen at the bedside — speaking the phrases, hearing the patient respond, adjusting your framing in real time.

The free 50-phrase PDF includes the most common clinical-Spanish phrases for oncology and diagnostic navigation conversations. And the full blog library covers thoracic surgery, pulmonology, cardiology, and over 160 other clinical specialties where Spanish-speaking patients frequently encounter information gaps that nurses are positioned to close.

All clinical scenarios in this post are composite and anonymized. Named patients are fictional constructs for educational illustration. The clinical content — staging criteria, Lung-RADS categories, pleurodesis criteria, chemoradiation protocols — reflects standard oncology practice at the time of publication and is not a substitute for institutional protocols or individual clinical judgment.